Jump to content

Template:COVID-19 vaccine candidates: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
details for CORVax12
m change ref templates
Line 374: Line 374:
|[[RNA vaccine|RNA]]
|[[RNA vaccine|RNA]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=3|participants=21000|description=Phase I/II/III (100+300+600+20,000=21,000): Randomized, double-blinded, placebo controlled.<ref>{{#invoke:Cite web| |date=2 August 2021|title=Arcturus to start clinical trial of COVID-19 vaccine in Vietnam|work=[[Reuters]]|url=https://www.reuters.com/business/healthcare-pharmaceuticals/arcturus-start-clinical-trial-covid-19-vaccine-vietnam-2021-08-02/}}</ref><ref>{{#invoke:Cite web| |date=2 August 2021|title=Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine|work=Biopharma Reporter|url=https://www.biopharma-reporter.com/Article/2021/08/02/Arcturus-Therapeutics-lines-up-clinical-trials-for-next-generation-mRNA-vaccine}}</ref>
|{{ClinicalStudyInfo|align=left|phase=1|endphase=3|participants=21000|description=Phase I/II/III (100+300+600+20,000=21,000): Randomized, double-blinded, placebo controlled.<ref>{{#invoke:Cite web| |date=2 August 2021|title=Arcturus to start clinical trial of COVID-19 vaccine in Vietnam|work=[[Reuters]]|url=https://www.reuters.com/business/healthcare-pharmaceuticals/arcturus-start-clinical-trial-covid-19-vaccine-vietnam-2021-08-02/}}</ref><ref>{{#invoke:Cite web| |date=2 August 2021|title=Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine|work=Biopharma Reporter|url=https://www.biopharma-reporter.com/Article/2021/08/02/Arcturus-Therapeutics-lines-up-clinical-trials-for-next-generation-mRNA-vaccine}}</ref>
|whenwhere=Aug-Oct 2021, Vietnam<ref>{{cite document |title=The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (ARCT-154-01) |date=19 August 2021 |url=https://clinicaltrials.gov/ct2/show/NCT05012943 |publisher=United States National Library of Medicine |id=NCT05012943 |access-date=19 August 2021 }}</ref>
|whenwhere=Aug-Oct 2021, Vietnam<ref>{{cite web |title=The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (ARCT-154-01) |date=19 August 2021 |url=https://clinicaltrials.gov/ct2/show/NCT05012943 |publisher=United States National Library of Medicine |id=NCT05012943 |access-date=19 August 2021 }}</ref>
}}
}}
|{{ClinicalStudyInfo|align=left|phase=pre
|{{ClinicalStudyInfo|align=left|phase=pre
Line 383: Line 383:
|China
|China
| [[Subunit vaccine|Subunit]]
| [[Subunit vaccine|Subunit]]
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=150|references=<ref>{{cite document |title=Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults |date=6 July 2021 |url=https://clinicaltrials.gov/ct2/show/NCT04950751 |publisher=United States National Library of Medicine |id=NCT04950751 |access-date=6 July 2021 }}</ref>|description=Randomized, controlled, observer-blind.
|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=150|references=<ref>{{cite web |title=Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults |date=6 July 2021 |url=https://clinicaltrials.gov/ct2/show/NCT04950751 |publisher=United States National Library of Medicine |id=NCT04950751 |access-date=6 July 2021 }}</ref>|description=Randomized, controlled, observer-blind.
|whenwhere=Aug 2021{{snd}}Apr 2022, Australia
|whenwhere=Aug 2021{{snd}}Apr 2022, Australia
}}
}}

Revision as of 00:54, 15 September 2021

Edit with VisualEditor

Main article: COVID-19 vaccine clinical research
COVID‑19 vaccine candidates in Phase I–III trials[1][2][3]
(
)
Vaccine candidates,
developers, and sponsors 		Country of origin Type (technology) Current phase (participants)
design 		Completed phase[a] (participants)
Immune response 		Pending authorization
Novavax COVID-19 vaccine (Covovax)[4][5]
Novavax, CEPI 		United States Subunit[6][7][8]/virus-like particle[9][10] (SARS‑CoV‑2 recombinant spike protein nanoparticle with adjuvant) Phase III (49,600)
Randomised, observer-blinded, placebo-controlled trial[11]
Sep 2020 – Jan 2021, UK (15,000); Dec 2020 – Jun 2023, US, Mexico, Puerto Rico (33,000);[12] India (Phase II/III: 1,600)[13][14] 		Phase I–II (131)
IgG and neutralizing antibody response with adjuvant after booster dose.[15]
Emergency (11)
Sanofi–GSK COVID-19 vaccine (VAT00008, Vidprevtyn)
Sanofi Pasteur, GSK 		France, United Kingdom Subunit (SARS-CoV-2 S adjuvanted recombinant protein) Phase III (37,430)[27][28]
A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older.
May 2021 – Jan 2023, Colombia, Dominican Republic, Ghana, Honduras, India (3,000), Japan, Kenya,[29] Mexico,[30] Nigeria, Pakistan, Sri Lanka, Uganda, United States 		Phase I–II (1,160)
Phase I-IIa (440): Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older.[31]
Phase IIb (720): Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine With AS03 Adjuvant in Adults 18 Years of Age and Older.[32]
Sep 2020 – Apr 2022, United States
Emergency (4)
CureVac COVID-19 vaccine (CVnCoV)
CureVac, CEPI 		Germany RNA (unmodified RNA)[37] Phase III (44,433)[38][39][40][41][42]
Phase 2b/3 (39,693): Multicenter efficacy and safety trial in adults.
Phase 3 (2,360+180+1,200+1,000=4,740): Randomized, placebo-controlled, multicenter, some observer-blinded, some open-labeled.
Nov 2020 – Jun 2022, Argentina, Belgium, Colombia, Dominican Republic, France, Germany, Mexico, Netherlands, Panama, Peru, Spain[43] 		Phase I–II (944)[44][45]
Phase I (284): Partially blind, controlled, dose-escalation to evaluate safety, reactogenicity and immunogenicity.
Phase IIa (660):Partially observer-blind, multicenter, controlled, dose-confirmation.
Jun 2020 – Oct 2021, Belgium (phase I), Germany (phase I), Panama (phase IIa), Peru (phase IIa)
Emergency (2)
CoVLP[48][49]
Medicago, GSK 		Canada, United Kingdom Virus-like particles[b] (recombinant, plant-based with AS03) Phase III (30,918)
Event-driven, randomized, observer blinded, placebo-controlled[51]
Nov 2020 – Dec 2021, Brazil, Canada, United Kingdom, United States 		Phase I (180)
Neutralizing antibodies at day 42 after the first injection (day 21 after the second injection) were at levels 10x that of COVID-19 survivors.
Jul 2020 – Sept 2021, Canada[52]
Emergency (1)
Valneva COVID-19 vaccine[54][unreliable source?][55]
Valneva 		France Inactivated SARS‑CoV‑2 Phase III (4,769)[56][57][58]
Phase III (4,019+750): Randomized, observer-blind, controlled, non-inferiority.
Apr–Dec 2021, New Zealand, United Kingdom 		Phase I–II (3,039)
Phase I/II (153): Randomized, multi-center, double-blinded.
Phase II (2,886): A randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2.[59]
Dec 2020 – Jun 2021, United Kingdom
Emergency (2)
Nanocovax[62]
Nanogen Pharmaceutical Biotechnology JSC 		Vietnam Subunit (SARS‑CoV‑2 recombinant spike protein with aluminum adjuvant)[63][64] Phase III (13,000)[65][66]
Adaptive, multicenter, randomized, double-blind, placebo-controlled
Jun 2021 – Jul 2022, Vietnam 		Phase I–II (620)[67]
Phase I (60): Open label, dose escalation.
Phase II (560): Randomization, double-blind, multicenter, placebo-controlled.
Dec 2020 – Jun 2021, Vietnam
Emergency (1)
UB-612
United Biomedical,Inc, Vaxxinity, DASA 		Brazil, United States Subunit (Multitope peptide based S1-RBD-protein based vaccine) Phase III (18,320)[69][70]
Phase IIb/III (7,320): Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Response.
Phase III (11,000)
Jan 2021 – Mar 2023, Taiwan (phase 2b/3), India (phase 3)[71] 		Phase I–II (3,910)[72]
Phase 1 (60): Open-label study
Phase IIa (3,850): Placebo-controlled, Randomized, Observer-blind Study.
Sep 2020 – Jan 2021, Taiwan
Emergency (1)
Razi Cov Pars[74][75]
Razi Vaccine and Serum Research Institute 		Iran Subunit (Recombinant Spike protein) Phase III (41,128)[76]
Two parallel and equal groups, randomized, double blind, non-inferiority design, compared to Sinopharm vaccine.
Sep–Dec 2021, Iran 		Phase I–II (633)[77]
Phase I (133): Randomized, double blind, placebo controlled.
Phase II (500): Two parallel groups, randomized, double blind, placebo controlled.[78]
Jan–Jun 2021, Iran
TURKOVAC
Health Institutes of Turkey 		Turkey Inactivated SARS‑CoV‑2 Phase III (40,800)[79]
Randomized, double-blinded, multi-center, active-controlled.
Jun 2021 – Sep 2021, Turkey 		Phase I–II (294)[80][81]
Phase I (44): Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
Phase 2 (250): Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.
Nov 2020 – Apr 2021, Turkey
West China Hospital COVID-19 vaccine
Jiangsu Province Centers for Disease Control and Prevention, West China Hospital (WestVac Biopharma), Sichuan University 		China Subunit (recombinant with Sf9 cell) Phase III (40,000)[82]
Multicenter, randomized, double-blind, placebo-controlled.
Jun 2021 – Feb 2022, Indonesia, Kenya, the Philippines (5,000)[83] 		Phase I–II (5,128)[84][85][86]
Phase I (168): Single-center, Randomized, Placebo-controlled, Double-blind.
Phase IIa (960):Single-center, Randomized, Double-Blinded, Placebo-Controlled.
Phase IIb (4,000):Single-center, Randomized, Double-Blinded, Placebo-Controlled.
Aug 2020 – May 2021, China
SCB-2019[87][88]
Clover Biopharmaceuticals,[89][90] Dynavax Technologies,[91] CEPI 		China Subunit (spike protein trimeric subunit with combined CpG 1018 and aluminium adjuvant) Phase III (29,300)
Phase II/III (29,000): Randomized, double-blind, controlled.
Phase III (300): Double-blind, randomized, controlled.[92]
Mar 2021 – Oct 2022, Belgium, Brazil, Colombia, Dominican Republic, Germany, Nepal, Panama, the Philippines, Poland, South Africa, Ukraine 		Phase I–II (950)
Phase I (150): Randomized, Double-blind, Placebo-controlled, First-in-human.
Phase II (800): Multi-center, Double-blind, Randomized, Controlled.[93]
Jun 2020 – Oct 2021, Australia (phase 1), China (phase 2)
Walvax COVID-19 vaccine (ARCoV)[94]
PLA Academy of Military Science, Walvax Biotech,[95] Suzhou Abogen Biosciences 		China RNA Phase III (28,000)[96]
Multi-center, Randomized, Double-blind, Placebo-controlled
May–Nov 2021, China,[97] Colombia, Indonesia, Malaysia, Mexico, Nepal, Pakistan, Turkey 		Phase I–II (908)
Phase I (168)
Phase II (420)
Phase I/II (320)[98]
Jun 2020 – Oct 2021, China[99]
COVAX-19 (SpikoGen)[100]
Vaxine Pty Ltd,[101] Cinnagen[102] 		Australia, Iran Subunit (recombinant protein) Phase III (16,876)[103]
Randomized, Two-armed, Double-blind, Placebo controlled
Aug – Sep 2021, Iran 		Phase I–II (440)[104]
Phase I (40)
Phase II (400): Randomized, Two-armed, Double-blind, Placebo controlled.[105]
Jun 2020 – Jul 2021, Adelaide, Iran
GRAd-COV2[106][107]
ReiThera, Lazzaro Spallanzani National Institute for Infectious Diseases 		Italy Adenovirus vector (modified gorilla adenovirus vector, GRAd) Phase III (10,300)[108][109]
Randomized, stratified, observer-blind, placebo-controlled.
Mar–Oct 2021, Italy 		Phase I (90)[110]
Subjects (two groups: 18–55 and 65–85 years old) randomly receiving one of three escalating doses of GRAd-COV2 or a placebo, then monitored over a 24-week period. 93% of subjects who received GRAd-COV2 developed anti-bodies.
Aug–Dec 2020, Rome
Zhongyianke Biotech–Liaoning Maokangyuan Biotech COVID-19 vaccine
Zhongyianke Biotech, Liaoning Maokangyuan Biotech, Academy of Military Medical Sciences 		China Subunit (Recombinant) Phase III (14,600)[111]
International multicenter, randomized, double-blind, placebo-controlled.
Sep 2021–?, China 		Phase I–II (696)[112]
Phase I (216): Randomized, placebo-controlled, double-blind.
Phase II (480): Single-center, randomized, double blinded, placebo controlled.[113]
Oct 2020 – Jul 2021, China
GBP510
SK Bioscience Co. Ltd., GSK 		South Korea, United Kingdom Subunit (Recombinant protein nanoparticle with adjuvanted with AS03) Phase III (4,000)[114]
Randomized, active-controlled, observer-blind, parallel-group, multi-center.[115]
Aug 2021-Mar 2022, South Korea 		Phase I–II (580)[116][117]
Phase I-II (260-320): Placebo-controlled, randomized, observer-blinded, dose-finding.
Jan–Aug 2021, South Korea
Unnamed
National Vaccine and Serum Institute, Lanzhou Institute of Biological Products Co., Ltd., Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd., Zhengzhou University 		China Subunit (Recombinant) Phase III (1,800)[118]
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above.
Sep 2021 – Nov 2023, United Arab Emirates 		Phase I–II (3,580)[119]
Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older.
Apr 2021 – Oct 2022, China
Bio E COVID-19 (Corbevax)[120][121][122]
Biological E. Limited, Baylor College of Medicine,[123] CEPI 		India, United States Subunit (using an antigen) Phase III (1,268)[124]
Phase 2b/3: Single Arm, Prospective, multicentre.[125]
Apr – Aug 2021, India 		Phase I–II (360)[126]
Randomized, Parallel Group Trial
Nov 2020 – Feb 2021, India
Inovio COVID-19 Vaccine (INO-4800)[127][128]
Inovio, CEPI, Korea National Institute of Health, International Vaccine Institute 		South Korea, United States DNA vaccine (plasmid delivered by electroporation) Phase II–III (6,578)
Phase II/III (6,578): Randomized, placebo-controlled, multi-center.[129]
Nov 2020 – Sep 2022, United States (phase II/III)[c] 		Phase I–II (920)
Phase Ia (120): Open-label trial.
Phase Ib-IIa (160): Dose-Ranging Trial.[130]
Phase II (640): Randomized, double-blinded, placebo-controlled, dose-finding.[131]
April 2020 – Feb 2022, China (phase II), South Korea (phase Ib-IIa), United States
HGC019[132]
Gennova Biopharmaceuticals, HDT Biotech Corporation[133] 		India, United States RNA Phase II–III (4,400)[134]
A prospective, multicentre, randomized, active-controlled (with COVISHIELD), observer-blind study to evaluate safety, tolerability and immunogenicity in healthy adults.
Phase II (400)
Phase III (4,000)
Sep 2021 – ?, India 		Phase I–II (620)[135][136][137]
Randomized, phase I/II, placebo-controlled, dose-ranging, parallel-group, crossover, multi-centre study to evaluate the safety, tolerability and immunogenicity in healthy adult subjects.
Phase I (120) open-label study in healthy 18-70 year-olds.
Phase II (500) observer-blind study in healthy 18-75 year-olds.
Apr 2021 – Oct 2021, India
AG0302-COVID‑19[138][139]
AnGes Inc.,[140] AMED 		Japan DNA vaccine (plasmid) Phase II–III (500)
Randomized, double-blind, placebo controlled[141]
Nov 2020 – Apr 2021, Japan 		Phase I–II (30)
Randomized/non-randomized, single-center, two doses
Jun–Nov 2020, Osaka
202-CoV
Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech 		China Subunit (Spike protein (CHO cell) 202-CoV with CpG / alum adjuvant) Phase II (1,056)[142]
Randomized, Double-blinded, Placebo-controlled.
July–Dec 2021, China 		Phase I (144)[143]
Randomized, double-blinded, placebo-controlled.
July–Dec 2021, China
V-01
Livzon Mabpharm, Inc. 		China Subunit (SARS-CoV-2 recombinant fusion protein) Phase II (880)[144]
Randomized, double-blind, and placebo-controlled.
Mar–May 2021, China 		Phase I (180)[145]
Single-center, randomized, double-blind and placebo-controlled.
Feb–Mar 2021, China
DelNS1-2019-nCoV-RBD-OPT (DelNS1-nCoV-RBD LAIV)
Beijing Wantai Biological Pharmacy, University of Hong Kong 		China, Hong Kong Replicating Viral vector (flu-based-RBD[clarification needed]) Phase II (720)[146]
Nov 2020 – Dec 2021, China 		Phase I (175)[147]
Sep 2020 – Sep 2022, China (60), Hong Kong (115)
BriLife (IIBR-100)[148]
The Israel Institute for Biological Research 		Israel Vesicular stomatitis vector (recombinant) Phase II–III (550)[149]
Phase IIb/III (550): Randomized, multi-center, placebo-controlled.
Aug – Oct 2021, Israel 		Phase I–II (1,040)[150]
Randomized, multi-center, placebo-controlled, dose-escalation.
Oct 2020 – May 2021, Israel
Unnamed
Ihsan Gursel, Scientific and Technological Research Council of Turkey 		Turkey Virus-like particle Phase II (330)[151]
Randomized, parallel dose assigned, double blind, multi center.
Jun – Sep 2021, Turkey 		Phase I (36)[152]
double-blinded, randomised, placebo controlled.
Mar – May 2021, Turkey
COH04S1
City of Hope Medical Center 		United States Viral vector Phase II (240)[153]
Multi-center, observer-blinded, EUA vaccine-controlled, randomized.
Aug 2021 – Jun 2023, California 		Phase I (129)[154]
Dose Escalation Study.
Dec 2020 – Nov 2022, California
Unnamed
Tsinghua University, Tianjin Medical University,[155] Walvax Biotech 		China Viral vector Phase II (180)[156]
Jul–Nov 2021, China 		Phase I (30)[157]
May–Jun 2021, China
ABNCoV2
Bavarian Nordic.[158] Radboud University Nijmegen 		Denmark, Netherlands Virus-like particle Phase II (150)[159]
Single center, sequential dose-escalation, open labelled trial.
Aug 2021–2022, Denmark, Netherlands 		Phase I (42)[160]
Single center, sequential dose-escalation, open labelled trial.
Mar–Dec 2021, Netherlands
ARCT-154 (VBC-COV19-154 in Vietnam)[161][162][163]
Arcturus Therapeutics, Vinbiocare 		United States, Vietnam RNA Phase I–III (21,000)
Phase I/II/III (100+300+600+20,000=21,000): Randomized, double-blinded, placebo controlled.[164][165]
Aug-Oct 2021, Vietnam[166] 		Preclinical
SCB-2020S
Clover Biopharmaceuticals[167] 		China Subunit Phase I–II (150)[168]
Randomized, controlled, observer-blind.
Aug 2021 – Apr 2022, Australia 		Preclinical
NDV-HXP-S (ButanVac [pt], COVIVAC, HXP-GPOVac, Patria)
Icahn School of Medicine at Mount Sinai, Institute of Vaccines and Medical Biologicals,[169] Butantan Institute, Laboratorio Avimex, National Council of Science and Technology, Mahidol University, University of Texas at Austin 		Brazil, Mexico, Thailand, United States, Vietnam Newcastle disease virus (NDV) vector (expressing the spike protein of SARS-CoV-2, with or without the adjuvant CpG 1018)/Inactivated SARS‑CoV‑2 Phase I–II (6,439)
Randomized, placebo-controlled, observer-blind.
Mar 2021 – May 2022; Brazil (5,394), Mexico (Phase I: 90), Thailand (460),[170] Vietnam (495)[171][172] 		Preclinical
ARCT-021[173][174]
Arcturus Therapeutics, Duke–NUS Medical School 		United States, Singapore RNA Phase I–II (798)
Phase I/II (92): Randomized, double-blinded, placebo controlled
Phase II (600): Randomized, observer-blind, placebo-controlled, multiregional, multicenter trial in healthy adults to evaluate the safety, reactogenicity, and immunogenicity.[175]
Phase IIa (106): Open label extension trial to assess the safety and long-term immunogenicity by giving single-dose vaccine to the participants from the parent study that received placebo or were seronegative at screening.[176]
Aug 2020 – Apr 2022, Singapore, United States (phase IIa) 		Preclinical
VBI-2902[177]
Variation Biotechnologies 		United States Virus-like particle Phase I–II (780)[178]
Randomized, observer-blind, dose-escalation, placebo-controlled
Mar 2021 – Jun 2022, Canada 		Preclinical
ICC Vaccine[179]
Novavax 		United States Subunit Phase I–II (640)[180]
Randomized, observer-blinded.
Sep 2021 – Mar 2022, Australia 		Preclinical
Sanofi–Translate Bio COVID-19 vaccine (MRT5500)[181]
Sanofi Pasteur and Translate Bio 		France, United States RNA Phase I–II (415)[182]
Interventional, randomized, parallel-group, sequential study consisting of a sentinel cohort followed by the full enrollment cohort. The sentinel cohort is a open-label, step-wise, dose-ranging study to evaluate the safety of 3 dose levels with 2 vaccinations. The full enrollment cohort is a quadruple-blinded study of safety and immunogenicity in 2 age groups, with half receiving a single injection, and the other half receiving 2 injections.
Mar 2021 – Sep 2022, Honduras, United States, Australia 		Preclinical
EuCorVac-19[183]
EuBiologics Co 		South Korea Subunit (spike protein using the recombinant protein technology and with an adjuvant) Phase I–II (280)
Dose-exploration, randomized, observer-blind, placebo-controlled
Feb 2021 – Mar 2022, the Philipppines (phase II), South Korea (phase I/II) 		Preclinical
RBD SARS-CoV-2 HBsAg VLP
SpyBiotech 		United Kingdom Virus-like particle Phase I–II (280)[184]
Randomized, placebo-controlled, multi-center.
Aug 2020 – ?, Australia 		Preclinical
GX-19 (GX-19N)[185][186][187]
Genexine consortium,[188][189] International Vaccine Institute 		South Korea DNA Phase I–II (410)
Phase I-II (170+210+30): Multi-center, some open-labeled, some double-blinded, single arm, randomized, placebo-controlled
Jun 2020 – Jul 2021, Seoul 		Preclinical
AV-COVID-19
AIVITA Biomedical, Inc., Ministry of Health (Indonesia) 		United States, Indonesia Dendritic cell vaccine (autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF) Phase I–II (202)[190][191]
Adaptive.
Dec 2020 – Feb 2022, Indonesia (phase I), United States (phase I/II) 		Preclinical
COVID-eVax
Takis Biotech 		Italy DNA Phase I–II (160)[192]
Multicenter, open label.
Phase I: First-in-human, dose escalation.
Phase II: single arm or two arms, randomized, dose expansion.
Feb–Sep 2021, Italy 		Preclinical
BBV154[193]
Bharat Biotech[194] 		India Adenovirus vector (intranasal) Phase I–II (375)[193][195]
Phase I (175): Randomized, double-blinded, multicenter.
Phase II (200): Randomized, double blind, multicenter.[196]
Mar 2021–?, India 		Preclinical
ChulaCov19
Chulalongkorn University 		Thailand RNA Phase I–II (72)[197]
Phase 1 (72): single-center, dose-escalation, first in human study in 2 age groups: 18-55 years-old and 56-75 years-old.
Phase 2: Multi-center, observer-blinded, placebo-controlled study to assess the safety, reactogenicity, and immunogenicity in healthy adults between 18-75 years old.
May-September 2021, Thailand 		Preclinical
COVID‑19/aAPC[198]
Shenzhen Genoimmune Medical Institute[199] 		China Lentiviral vector (with minigene modifying aAPCs) Phase I (100)[198]
Single group, open-label study to evaluate safety and immunity.
Feb 2020 – Dec 2024, Shenzhen 		Preclinical
LV-SMENP-DC[200]
Shenzhen Genoimmune Medical Institute[199] 		China Lentiviral vector (with minigene modifying DCs) Phase I–II (100)[200]
Single-group, open label, multi-center study to evaluate safety and efficacy.
Mar 2020 – Dec 2024, Shenzhen 		Preclinical
ImmunityBio COVID-19 vaccine (hAd5)
ImmunityBio 		United States Viral vector Phase I–II (540)[201][202][203][204][205]
Phase 1/2 Study of the Safety, Reactogenicity, and Immunogenicity of a Subcutaneously- and Orally- Administered Supplemental Spike & Nucleocapsid-targeted COVID-19 Vaccine to Enhance T Cell Based Immunogenicity in Participants Who Have Already Received Prime + Boost Vaccines Authorized For Emergency Use.
Oct 2020  – Sep 2021, South Africa, United States 		Preclinical
PTX-COVID19-B[206]
Providence Therapeutics 		Canada RNA Phase I (60)[206]
First-in-Human, Observer-Blinded, Randomized, Placebo Controlled.[207]
Jan–May 2021, Canada 		Preclinical
COVAC-2[208]
VIDO (University of Saskatchewan) 		Canada Subunit (spike protein + SWE adjuvant) Phase I (108)[208]
Randomized, observer-blind, dose-escalation.[209]
Feb 2021 – Oct 2022, Halifax 		Preclinical
COVI-VAC (CDX-005)[210]
Codagenix Inc. 		United States Attenuated Phase I (48)[211]
First-in-human, randomised, double-blind, placebo-controlled, dose-escalation
Dec 2020 – Jun 2021, United Kingdom 		Preclinical
CoV2 SAM (LNP)
GSK 		United Kingdom RNA Phase I (40)[212]
Open-label, dose escalation, non-randomized
Feb–Jun 2021, United States 		Preclinical
COVIGEN[213]
Bionet Asia, Technovalia, University of Sydney 		Australia, Thailand DNA Phase I (150)[214]
Double-blind, dose-ranging, randomised, placebo-controlled.
Feb 2021 – Jun 2022, Australia, Thailand 		Preclinical
MV-014-212[215]
Meissa Vaccine Inc. 		United States Attenuated Phase I (130)[216]
Randomized, double-blinded, multicenter.
Mar 2021 – Oct 2022, United States 		Preclinical
S-268019
Shionogi 		Japan Subunit Phase I–II (300)[217]
Randomized, double-blind, placebo-controlled, parallel-group.
Dec 2020 – Jun 2022, Japan 		Preclinical
KBP-201
Kentucky Bioprocessing 		United States Subunit Phase I–II (180)[218]
First-in-human, observer-blinded, randomized, placebo-controlled, parallel group
Dec 2020 – May 2022, United States 		Preclinical
AdCLD-CoV19
Cellid Co 		South Korea Viral vector Phase I–II (150)[219]
Phase I: Dose Escalation, Single Center, Open.
Phase IIa: Multicenter, Randomized, Open.
Dec 2020 – Jul 2021, South Korea 		Preclinical
AdimrSC-2f
Adimmune Corporation 		Taiwan Subunit (Recombinant RBD +/− Aluminium) Phase I (70)[220]
Randomized, single center, open-label, dose-finding.
Aug–Nov 2020, Taiwan 		Preclinical
AKS-452
University Medical Center Groningen 		Netherlands Subunit Phase I–II (130)[221]
Non-randomized, Single-center, open-label, combinatorial.
Apr–Jun 2021, Netherlands 		Preclinical
GLS-5310
GeneOne Life Science Inc. 		South Korea DNA Phase I–II (345)[222]
Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind.
Dec 2020 – Jul 2022, South Korea 		Preclinical
Covigenix VAX-001
Entos Pharmaceuticals Inc. 		Canada DNA Phase I–II (72)[223]
Placebo-controlled, randomized, observer-blind, dose ranging adaptive.
Mar–Aug 2021, Canada 		Preclinical
NBP2001
SK Bioscience Co. Ltd. 		South Korea Subunit (Recombinant protein with adjuvanted with alum) Phase I (50)[224]
Placebo-controlled, Randomized, Observer-blinded, Dose-escalation.
Dec 2020 – Apr 2021, South Korea 		Preclinical
CoVac-1
University of Tübingen 		Germany Subunit (Peptide) Phase I–II (104)[225][226]
Phase I (36): Placebo-controlled, Randomized, Observer-blinded, Dose-escalation.
Phase I/II (68): B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency.
Nov 2020 – Feb 2022, Germany 		Preclinical
bacTRL-Spike
Symvivo 		Canada DNA Phase I (24)[227]
Randomized, observer-blind, placebo-controlled.
Nov 2020 – Feb 2022, Australia 		Preclinical
CORVax12
Providence Health & Services 		United States DNA Phase I (36)[228]
Open-label, non-randomized, parallel assignment study to evaluate the safety of prime & boost doses with/without the combination of electroporated IL-12p70 plasmid in 2 age groups: 18-50 years-old and > 50 years-old.
Dec 2020 – Jul 2021, United States 		Preclinical
ChAdV68-S (SAM-LNP-S)
NIAID, Gritstone Oncology 		United States Viral vector Phase I (150)[229]
Open-label, dose and age escalation, parallel design.
Mar 2021 – Sep 2022, United States 		Preclinical
VXA-CoV2-1 (VXA-NVV-104)
Vaxart 		United States Viral vector Phase I (83)[230][231]
Phase Ia (35): Double-blind, randomized, placebo-controlled, first-in-Human.
Phase Ib (48): Multicenter, randomized, double-blind, placebo-controlled.
Sep 2020 – Aug 2021, United States 		Preclinical
SpFN COVID-19 vaccine
United States Army Medical Research and Development Command 		United States Subunit Phase I (72)[232]
Randomized, double-blind, placebo-controlled.
Apr 2021 – Oct 2022, United States 		Preclinical
MVA-SARS-2-S (MVA-SARS-2-ST)
University Medical Center Hamburg-Eppendorf 		Germany Viral vector Phase I–II (270)[233][234]
Phase I (30): Open, Single-center.
Phase Ib/IIa (240): Multi-center, Randomized Controlled.
Oct 2020 – Mar 2022, Germany 		Preclinical
ReCOV
Jiangsu Rec-Biotechnology Co Ltd 		China Subunit (Recombinant two-component spike and RBD protein (CHO cell)) Phase I (160)[235]
First-in-human, randomized, double-blind, placebo-controlled, dose-finding.
Jun–Dec 2021, New Zealand 		Preclinical
Koçak-19 Inaktif Adjuvanlı COVID-19 vaccine
Kocak Farma 		Turkey Inactivated SARS‑CoV‑2 Phase I (38)[236]
Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
Mar–Jun 2021, Turkey 		Preclinical
mRNA-1283
Moderna 		United States RNA Phase I (106)[237]
Randomized, observer-blind, dose-ranging study.
Mar 2021 – Apr 2022, United States 		Preclinical
DS-5670[238]
Daiichi Sankyo[239] 		Japan RNA Phase I–II (152)[240]
A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects.
Mar 2021 – Jul 2022, Japan 		Preclinical
CoV2-OGEN1
Syneos Health, US Specialty Formulations 		United States Subunit Phase I (45)[241]
First-In-Human
Jun–Dec 2021, New Zealand 		Preclinical
KD-414
KM Biologics Co 		Japan Inactivated SARS‑CoV‑2 Phase I–II (210)[242]
Randomized, double blind, placebo control, parallel group.[243]
Mar 2021 – Dec 2022, Japan 		Preclinical
CoVepiT
OSE Immunotherapeutics 		France Subunit Phase I (48)[244][245]
Randomized, open label.
Apr–Sept 2021, France 		Preclinical
HDT-301
Senai Cimatec 		Brazil RNA Phase I (90)[246]
Randomized, open-label, dose-escalation.
Aug 2021–Sep 2022, Brazil 		Preclinical
SC-Ad6-1
Tetherex Pharmaceuticals 		United States Viral vector Phase I (40)[247]
First-In-Human, Open-label, Single Ascending Dose and Multidose.
Jun–Dec 2021, Australia 		Preclinical
Unnamed
Osman ERGANIS, Scientific and Technological Research Council of Turkey 		Turkey Inactivated SARS‑CoV‑2 Phase I (50)[248]
Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.
Apr–Oct 2021, Turkey 		Preclinical
EXG-5003
Elixirgen Therapeutics, Fujita Health University 		Japan, United States RNA Phase I–II (60)[249]
First in Human, randomized, placebo-controlled.
Apr 2021 – Jan 2023, Japan 		Preclinical
mRNACOVID-19 Vaccine
Stemirna Therapeutics Co. Ltd. 		China RNA Phase I (240)[250]
Randomized, double-blind, placebo-controlled.
Mar–Jul 2021, China 		Preclinical
IVX-411
Icosavax, Seqirus Inc. 		United States Virus-like particle Phase I–II (168)[251][252]
Phase I/II (84): Randomized, observer-blinded, placebo-controlled.
Jun 2021–2022, Australia 		Preclinical
QazCoVac-P[253]
Research Institute for Biological Safety Problems 		Kazakhstan Subunit Phase I–II (244)[254]
Phase I: Randomized, blind, placebo-controlled.
Phase II: Randomized, open phase.
Jun – Dec 2021, Kazakhstan 		Preclinical
LNP-nCOV saRNA-02
MRC/UVRI & LSHTM Uganda Research Unit 		Uganda RNA Phase I (42)[255]
A Clinical Trial to Assess the Safety and Immunogenicity of LNP-nCOV saRNA-02, a Self-amplifying Ribonucleic Acid (saRNA) Vaccine, in SARS-CoV-2 Seronegative and Seropositive Uganda Population.
Sep 2021 – Jun 2022, Uganda 		Preclinical
Noora[256]
Baqiyatallah University of Medical Sciences 		Iran Subunit (RBD protein recombinant vaccine) Phase I (70)[257]
Randomized, double-blinded, placebo-controlled.
Jun–Aug 2021, Iran 		Preclinical
Baiya SARS-CoV-2 Vax 1[258]
Baiya Phytopharm Co Ltd. 		Thailand Plant-based Subunit (RBD-Fc + adjuvant) Phase I (96)[259]
Randomized, open-label, dose-finding.
Sep–Dec 2021, Thailand 		Preclinical
CVXGA1
CyanVac LLC 		United States Viral vector Phase I (80)[260]
Open-label
July–Dec 2021, United States 		Preclinical
Unnamed
St. Petersburg Scientific Research Institute of Vaccines and Sera of Russia at the Federal Medical Biological Agency 		Russia Subunit (Recombinant) Phase I–II (200)[261]
July–? 2021, Russia 		Preclinical
LVRNA009
Liverna Therapeutics Inc. 		China RNA Phase I (24)[262]
July–Nov 2021, China 		Preclinical
PHH-1V
Hipra[263] 		Spain Subunit Phase I–II (30)[264]
Randomized, controlled, observer-blinded, dose-escalation.
Aug–Nov 2021, Spain 		Preclinical
Versamune-CoV-2FC [pt]
Farmacore Biotechnology, PDS Biotechnology Corporation, Faculty of Medicine of Ribeirão Preto 		Brazil, United States Subunit Phase I–II (360)[265]
Double-blind, randomized controlled.
Nov 2021–Mar 2022, Brazil 		Preclinical
ARCT-165
Arcturus Therapeutics 		United States RNA Phase I–II (72)[266]
Randomized, observer-blind.
Aug 2021–Mar 2023, Singapore, United States 		Preclinical
BCD-250
Biocad 		Russia Viral vector Phase I–II (160)[267]
Randomized, double-blind, placebo-controlled, adaptive, seamless phase I/II.
Aug 2021–Aug 2022, Russia 		Preclinical
Unnamed
North's Academy of Medical Science Medical biology institute 		North Korea Subunit (spike protein with Angiotensin-converting enzyme 2) Phase I–II (?)[268]
Jul 2020, North Korea 		Preclinical
Unnamed
Sinopharm 		China Subunit Phase I–II (?)[269]
Apr 2021–?, China 		Preclinical
Vabiotech COVID-19 vaccine
Vaccine and Biological Production Company No. 1 (Vabiotech) 		Vietnam Subunit Preclinical
Awaited for the conduct on Phase I trial.[270] 		?
INO-4802
Inovio 		United States DNA Preclinical
Awaited for the conduct on Phase I/II trials.[271] 		?
Bangavax (Bancovid)[272][273]
Globe Biotech Ltd. of Bangladesh 		Bangladesh RNA Preclinical
Awaiting for approval from Bangladesh government to conduct the first clinical trial.[274] 		?
Unnamed
Indian Immunologicals, Griffith University[275] 		Australia, India Attenuated Preclinical ?
EPV-CoV-19[276]
EpiVax 		United States Subunit (T cell epitope-based protein) Preclinical ?
Unnamed
Intravacc[277] 		Netherlands Subunit Preclinical ?
CV2CoV[278]
CureVac, GSK 		Germany, United Kingdom RNA Preclinical ?
DYAI-100[279] Sorrento Therapeutics, Dyadic International, Inc.[280] United States Subunit Preclinical ?
Unnamed[281]
Ministry of Health (Malaysia), Malaysia Institute of Medical Research Malaysia, Universiti Putra Malaysia 		Malaysia RNA Preclinical ?
AdCOVID
Altimmune Inc. 		United States Viral vector Terminated (180)[282][283]
Double-blind, randomized, placebo-controlled, first-in-Human.
Feb 2021 – Feb 2022, United States 		Preclinical
LNP-nCoVsaRNA[284]
MRC clinical trials unit at Imperial College London 		United Kingdom RNA Terminated (105)
Randomized trial, with dose escalation study (15) and expanded safety study (at least 200)
Jun 2020 – Jul 2021, United Kingdom 		?
TMV-083
Institut Pasteur 		France Viral vector Terminated (90)[285]
Randomized, Placebo-controlled.
Aug 2020 – Jun 2021, Belgium, France 		?
SARS-CoV-2 Sclamp/V451[286][287][unreliable source?]
UQ, Syneos Health, CEPI, Seqirus 		Australia Subunit (molecular clamp stabilized spike protein with MF59) Terminated (120)
Randomised, double-blind, placebo-controlled, dose-ranging.
False positive HIV test found among participants.
Jul–Oct 2020, Brisbane 		?
V590[288] and V591/MV-SARS-CoV-2[289] Merck & Co. (Themis BIOscience), Institut Pasteur, University of Pittsburgh's Center for Vaccine Research (CVR), CEPI United States, France Vesicular stomatitis virus vector[290] / Measles virus vector[291][unreliable source?] Terminated
In phase I, immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.[292]
  1. ^ Latest Phase with published results.
  2. ^ Virus-like particles grown in Nicotiana benthamiana[50]
  3. ^ Phase I–IIa in South Korea in parallel with Phase II–III in the US

References

These references will appear in the article, but this list appears only on this page.
  1. ^ "COVID-19 vaccine tracker (Refresh URL to update)". vac-lshtm.shinyapps.io. London School of Hygiene & Tropical Medicine. 12 July 2021. Retrieved 10 March 2021.
  2. ^ "COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)". Milken Institute. 8 December 2020. Retrieved 11 December 2020. {{cite web}}: Unknown parameter |lay-url= ignored (help)
  3. ^ "Draft landscape of COVID 19 candidate vaccines". World Health Organization (WHO). 10 December 2020. Retrieved 11 December 2020.
  4. ^ "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". ClinicalTrials.gov. 30 April 2020. NCT04368988. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
  5. ^ "Hope to launch Covovax by September, says Serum Institute CEO". mint. 27 March 2021. Retrieved 28 March 2021.
  6. ^ Wadman M (November 2020). "The long shot". Science. 370 (6517): 649–53. Bibcode:2020Sci...370..649W. doi:10.1126/science.370.6517.649. PMID 33154120.
  7. ^ Wadman M (28 December 2020). "Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays". Science. doi:10.1126/science.abg3441. S2CID 234411557.
  8. ^ Parekh N (24 July 2020). "Novavax: A SARS-CoV-2 Protein Factory to Beat COVID-19". Archived from the original on 22 November 2020. Retrieved 24 July 2020.
  9. ^ Chung YH, Beiss V, Fiering SN, Steinmetz NF (October 2020). "COVID-19 Vaccine Frontrunners and Their Nanotechnology Design". ACS Nano. 14 (10): 12522–37. doi:10.1021/acsnano.0c07197. PMC 7553041. PMID 33034449.
  10. ^ Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D (June 2020). "Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles". ACS Nano. 14 (6): 7617–27. doi:10.1021/acsanm.0c01978. PMC 7482545. PMID 32437124.
  11. ^ "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom". Retrieved 22 November 2020.
  12. ^ "A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2". Retrieved 30 December 2020.
  13. ^ "The study to check the safety and immune response of (Covid-19 vaccine) COVOVAX in adults". ctri.nic.in. Clinical Trials Registry- India. 25 February 2021. Retrieved 15 June 2021.{{cite web}}: CS1 maint: url-status (link)
  14. ^ "Covovax trials begin in India, launch hopefully in September: Adar Poonawalla". India Today. 27 March 2021. Retrieved 28 March 2021.
  15. ^ Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. (December 2020). "Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine". The New England Journal of Medicine. 383 (24): 2320–32. doi:10.1056/NEJMoa2026920. PMC 7494251. PMID 32877576.
  16. ^ "Trudeau Signs Deal to Make Novavax Covid-19 Vaccine in Canada". Bloomberg.com. 2 February 2021. Retrieved 1 April 2021.
  17. ^ "EMA starts rolling review of Novavax's COVID-19 vaccine (NVX-CoV2373)". European Medicines Agency (EMA) (Press release). 1 December 2020. Retrieved 12 February 2021.
  18. ^ "Ukraine secures 12 million AstraZeneca, Novavax COVID-19 vaccine doses". Reuters. 5 February 2021. Retrieved 24 February 2021.
  19. ^ "COVID-19: Ukraine set to launch coronavirus vaccination programme". euronews. 8 February 2021. Retrieved 24 February 2021.
  20. ^ "AstraZeneca and Novavax COVID Vaccines: What We Know So Far". NBC Chicago. Retrieved 1 April 2021.
  21. ^ "UK secures deal to bottle 60m Novavax vaccine doses in the North East". CityAM. 29 March 2021. Retrieved 1 April 2021.
  22. ^ "Novavax COVID vaccine takes first step toward Australian approval". Regulatory Affairs Professionals Society (RAPS). Retrieved 1 April 2021.
  23. ^ biopharma-reporter.com. "New Zealand secures COVID-19 vaccines from Novavax and AstraZeneca". BioPharma-Reporter. Retrieved 1 April 2021.
  24. ^ "S.Korea says Novavax, Sputnik V COVID-19 vaccines submitted for regulatory approval". 29 April 2021.
  25. ^ Magsambol, Bonz (6 August 2021). "Novavax applies for emergency use of its COVID-19 vaccine in Philippines". Rappler.
  26. ^ a b "Novavax seeks COVID-19 vaccine use in India, Indonesia, the Philippines ahead of U.S." CP24. 5 August 2021. Retrieved 6 August 2021.
  27. ^ "Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". ClinicalTrials.gov. 27 May 2021. NCT04904549. Retrieved 28 May 2021.
  28. ^ "Safety and efficacy of Monovalent and Bivalent Recombinant Protein Vaccines against COVID-19 in Adults 18 Years of Age and Older". ctri.nic.in. Clinical Trials Registry India. CTRI/2021/06/034442. Retrieved 3 August 2021.
  29. ^ "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.
  30. ^ "Tarjeta del participante del estudio VAT00008: ejemplo central para adaptación a nivel de país" [VAT00008 Study Participant Card: Central Example for Country-Level Adaptation] (PDF). incmnsz.mx. Salvador Zubirán National Institute of Health Sciences and Nutrition. 15 April 2021.
  31. ^ "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older". ClinicalTrials.gov. 3 September 2020. NCT04537208. Retrieved 11 March 2021.
  32. ^ "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)". ClinicalTrials.gov. 21 February 2021. NCT04762680. Retrieved 11 March 2021.
  33. ^ "Sanofi and GSK confirm agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine". GSK (Press release). Retrieved 1 April 2021.
  34. ^ "Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine". GSK (Press release). Retrieved 1 April 2021.
  35. ^ "U.S. Likely to Get Sanofi Vaccine First If It Succeeds". Bloomberg.com. 13 May 2020. Retrieved 1 April 2021.
  36. ^ "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News Online. 29 July 2020. Retrieved 1 April 2021.
  37. ^ "COVID-19". CureVac. Retrieved 21 December 2020.
  38. ^ "A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19". ClinicalTrials.gov. 3 December 2020. NCT04652102. Retrieved 22 July 2021.
  39. ^ "A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19". ClinicalTrials.gov. 19 December 2020. NCT04674189. Retrieved 23 March 2021.
  40. ^ "A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19". ClinicalTrials.gov. 9 April 2021. NCT04838847. Retrieved 26 April 2021.
  41. ^ "A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19". ClinicalTrials.gov. 26 April 2021. NCT04860258. Retrieved 26 April 2021.
  42. ^ "COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)". ClinicalTrials.gov. 19 April 2021. NCT04848467. Retrieved 18 June 2021.
  43. ^ "COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older". EU Clinical Trials Register. 19 November 2020. 2020-003998-22. Retrieved 19 December 2020.
  44. ^ "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". ClinicalTrials.gov. 26 June 2020. NCT04449276. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  45. ^ "A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19". ClinicalTrials.gov. 17 August 2020. NCT04515147. Archived from the original on 23 August 2020. Retrieved 28 August 2020.
  46. ^ "EMA starts rolling review of CureVac's COVID-19 vaccine (CVnCoV)". European Medicines Agency (EMA) (Press release). 1 December 2020. Retrieved 12 February 2021.
  47. ^ "CureVac seeks Covid-19 shot approval in Switzerland". Swissinfo. 20 April 2021. Retrieved 22 April 2021.
  48. ^ "GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine". PMLive. 13 November 2020. Retrieved 16 November 2020.
  49. ^ "Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate" (Press release). GlaxoSmithKline. 16 March 2021. Retrieved 13 April 2021.
  50. ^ Chander V (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Archived from the original on 16 July 2020. Retrieved 14 July 2020.
  51. ^ "Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults". ClinicalTrials.gov. 19 November 2020. NCT04636697. Retrieved 26 November 2020.
  52. ^ "Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years". ClinicalTrials.gov. 29 June 2020. NCT04450004. Retrieved 17 March 2021.
  53. ^ "Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine". Medicago (Press release). Retrieved 1 April 2021.
  54. ^ "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Retrieved 11 January 2021.
  55. ^ "Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults". U.S. National Library of Medicine. 30 December 2020. Retrieved 11 January 2021.
  56. ^ "Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001" (Press release). Valneva. 21 April 2021. Retrieved 22 April 2021.
  57. ^ "Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)". ClinicalTrials.gov. 29 April 2021. NCT04864561.
  58. ^ "Immunogenicity of VLA2101 Compared to VLA2001". ClinicalTrials.gov. 9 July 2021. NCT04956224.
  59. ^ "Evaluating COVID-19 Vaccination Boosters". isrctn.com. ISRCTN Registry. Retrieved 6 June 2021.
  60. ^ Balfour H (15 January 2021). "Valneva may provide Europe with the only inactivated virus vaccine for COVID-19". European Pharmaceutical Review.
  61. ^ "Valneva Seeks UK Approval for Covid-19 Vaccine".
  62. ^ "VN starts injection of homegrown COVID-19 vaccine in first-stage human trial". Viet Nam News. 17 December 2020.
  63. ^ "Draft landscape and tracker of COVID-19 candidate vaccines". World Health Organization (WHO). 26 February 2021.
  64. ^ "How much does first Made-in Vietnam COVID-19 vaccine cost?". Voice of Vietnam. 11 December 2020.
  65. ^ "Local Nanocovax vaccine's phase 3 trial to begin next week". vietnamnet.vn. 26 May 2021. Retrieved 28 May 2021.
  66. ^ "Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19". ClinicalTrials.gov. 11 June 2021. NCT04922788. Retrieved 11 June 2021.
  67. ^ Le C, Thu A (26 February 2021). "Vietnam enters second phase of Covid-19 vaccine trials". VnExpress.
  68. ^ Onishi T (15 June 2021). "Vietnam homegrown COVID vaccine heads for full approval by year-end". Nikkei Asia.
  69. ^ "A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers". ClinicalTrials.gov. 26 February 2021. NCT04773067. Retrieved 20 March 2021.
  70. ^ "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine". ClinicalTrials.gov. 24 December 2020. NCT04683224. Retrieved 20 March 2021.
  71. ^ Liao, George (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
  72. ^ "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine". ClinicalTrials.gov. 11 September 2020. NCT04545749. Retrieved 20 March 2021.
  73. ^ Strong, Matthew (30 June 2021). "Taiwan's United Biomedical applies for COVID vaccine EUA". Taiwan News.
  74. ^ "COVID-19 vaccine Razi Cov Pars starts third clinical trial phase". Tehran Times. 2021-08-27. Retrieved 2021-08-30.
  75. ^ "Razi Vaccine and Serum Research Institute - English-Home". english.rvsri.ac.ir. Retrieved 2021-08-30.{{cite web}}: CS1 maint: url-status (link)
  76. ^ "Comparison of the safety and efficacy of Razi SARS-CoV-2 recombinant Spike protein (Razi Cov Pars) and Sinopharm vaccines in adults aged 18 and over, a phase III randomised, double blind, non-inferiority clinical trial". Iranian Registry of Clinical Trials. Retrieved 29 August 2021.
  77. ^ "Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18–55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 μg/200μl); a Randomised, double blind, clinical trial". irct.ir. Iranian Registry of Clinical Trials. Retrieved 21 March 2021.
  78. ^ "Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18–70 years; a Randomised, double blind, parallel 2 arms clinical trial". Iranian Registry of Clinical Trials. Retrieved 22 April 2021.
  79. ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
  80. ^ "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)". ClinicalTrials.gov. 31 December 2020. NCT04691947. Retrieved 21 March 2021.
  81. ^ "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". ClinicalTrials.gov. 1 April 2021. NCT04824391. Retrieved 4 April 2021.
  82. ^ "A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)". ClinicalTrials.gov. 27 May 2021. NCT04904471. Retrieved 28 May 2021.
  83. ^ "A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older". registry.healthresearch.ph. PHRR210712-003704.
  84. ^ "Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". ClinicalTrials.gov. 28 August 2020. NCT04530656. Retrieved 20 March 2021.
  85. ^ "A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". ClinicalTrials.gov. 23 November 2020. NCT04640402. Retrieved 20 March 2021.
  86. ^ "Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". ClinicalTrials.gov. 22 January 2021. NCT04718467. Retrieved 20 March 2021.
  87. ^ "SCB-2019 as COVID-19 Vaccine". ClinicalTrials.gov. 28 May 2020. NCT04405908. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  88. ^ "Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 20 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  89. ^ "About Us". Clover Biopharmaceuticals. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  90. ^ "A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)". ClinicalTrials.gov. 17 December 2020. NCT04672395. Retrieved 10 March 2021.
  91. ^ "Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate". Dynavax. 24 March 2021. Retrieved 7 June 2021.
  92. ^ "A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases". ClinicalTrials.gov. 19 August 2021. NCT05012787. Retrieved 19 August 2021.
  93. ^ "Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults in China". ClinicalTrials.gov. 8 July 2021. NCT04954131. Retrieved 8 July 2021.
  94. ^ "A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above". Chinese Clinical Trial Register. 24 June 2020. ChiCTR2000034112. Archived from the original on 11 October 2020. Retrieved 6 July 2020.
  95. ^ "Company introduction". Walvax Biotechnology. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  96. ^ "A Phase III Clinical Study to Evaluate the Protective Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate in Population Aged 18 Years and Above". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 17 April 2020.
  97. ^ "A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine in Population Aged 18 Years and Older". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 21 July 2021.
  98. ^ "A Phase I/II Clinical Trial to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine in Healthy Population Aged 60 Years and Older". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 2 August 2021.
  99. ^ "A Phase II clinical trial to evaluate the immunogenicity and safety of different doses of a novel coronavirus pneumonia (COVID-19) mRNA vaccine in population aged 18-59 years". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 20 March 2021.
  100. ^ "Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)". ClinicalTrials.gov. 29 June 2021. NCT04944368. Retrieved 29 June 2021.
  101. ^ "Vaxine". Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  102. ^ ""Spikogen", A Joint Venture Between Vaxine And Cinnagen". Vaxine.
  103. ^ "A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)". irct.ir. 2 August 2021. IRCT20150303021315N24. Retrieved 3 August 2021.{{cite web}}: CS1 maint: url-status (link)
  104. ^ "Monovalent Recombinant COVID19 Vaccine (COVAX19)". ClinicalTrials.gov. 1 July 2020. NCT04453852. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  105. ^ "A phase II, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)". Iranian Registry of Clinical Trials. Retrieved 28 May 2021.
  106. ^ "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. 27 August 2020. NCT04528641.
  107. ^ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
  108. ^ "Study of GRAd-COV2 for the Prevention of COVID-19 in Adults (COVITAR)". ClinicalTrials.gov. 10 March 2021. NCT04791423. Retrieved 20 March 2021.
  109. ^ "ReiThera's COVID-19 vaccine candidate enters Phase 2/3 clinical study". ReiThera. 18 March 2021. Retrieved 20 March 2021.
  110. ^ "New ReiThera vaccine safe, response peak at 4 wks". ANSA. 5 January 2021.
  111. ^ "Efficacy, safety and immunogenicity of a recombinant protein subunit vaccine (CHO cells) against COVID-19 in adults: an international multicenter, randomized, double-blind, placebo-controlled phase III study". chictr.org.cn. Chinese Clinical Trial Registry. 5 September 2021. ChiCTR2100050849. Retrieved 5 September 2021.
  112. ^ "Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)". ClinicalTrials.gov. United States National Library of Medicine. 19 November 2020. NCT04636333. Retrieved 13 April 2021.
  113. ^ "Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)". ClinicalTrials.gov. United States National Library of Medicine. 24 March 2021. NCT04813562. Retrieved 13 April 2021.
  114. ^ "SK Bioscience Submitted Phase 3 IND for COVID-19 Vaccine". SK Bioscience.
  115. ^ "A Phase III Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older". ClinicalTrials.gov. 17 August 2021. NCT05007951. Retrieved 17 August 2021.
  116. ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
  117. ^ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
  118. ^ "Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above". ClinicalTrials.gov. 3 September 2021. NCT05033847. Retrieved 3 September 2021.
  119. ^ "A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19". ClinicalTrials.gov. 3 May 2021. NCT04869592. Retrieved 4 May 2021.
  120. ^ Raghavan P (5 June 2021). "'At-risk' policy change: Govt puts money on new-platform Covid-19 vaccine". The Indian Express.
  121. ^ "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry – India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.
  122. ^ "CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. Coalition for Epidemic Preparedness Innovations. Retrieved 5 March 2021.
  123. ^ Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine.
  124. ^ "Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine". The Hindu. 24 April 2021.
  125. ^ "Biological E's CORBEVAX vaccine clinical study for protection against Covid-19 disease". ctri.nic.in. Clinical Trial Registry India. 4 June 2021. CTRI/2021/06/034014. Retrieved 9 June 2021.
  126. ^ Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint.
  127. ^ "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". ClinicalTrials.gov. 7 April 2020. NCT04336410. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  128. ^ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 16 April 2020. Retrieved 23 April 2020.
  129. ^ "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure". ClinicalTrials.gov. 24 November 2020. NCT04642638. Retrieved 12 March 2021.
  130. ^ "Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19". United States National Library of Medincine. Retrieved 12 March 2021.
  131. ^ "A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding Clinical Trial to Evaluate the Safety and Immunogenicity of Different Doses of COVID-19 DNA Vaccine INO-4800 Administered Intradermally Followed by Electroporation in Healthy Adult and Elderly Volunteers". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 27 March 2021.
  132. ^ "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
  133. ^ "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.
  134. ^ "Safety and immunogenicity study of an mRNA based vaccine (HGCO19) for COVID19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 9 September 2021.
  135. ^ Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
  136. ^ "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 5 June 2021.
  137. ^ "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". Cochrane COVID-19 Study Register. 2021-08-04. Archived from the original on 2021-09-11.
  138. ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  139. ^ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". ClinicalTrials.gov. 26 August 2020. NCT04527081. Retrieved 11 March 2021.
  140. ^ "About AnGes – Introduction". AnGes, Inc. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  141. ^ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". ClinicalTrials.gov. 7 December 2020. NCT04655625. Retrieved 11 March 2021.
  142. ^ "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)". ClinicalTrials.gov. 4 August 2021. NCT04990544. Retrieved 4 August 2021.
  143. ^ "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)". ClinicalTrials.gov. 4 July 2021. NCT04982068. Retrieved 29 July 2021.
  144. ^ "评价重组新型冠状病毒融合蛋白疫苗在健康人群安全性和免疫原性随机、双盲、安慰剂对照的I期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 21 April 2021.
  145. ^ "评价重组新型冠状病毒融合蛋白疫苗在健康人群免疫原性和安全性随机、双盲、安慰剂对照的II期临床试验". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 21 April 2021.
  146. ^ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 24 March 2021.
  147. ^ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 24 March 2021.
  148. ^ "A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults". ClinicalTrials.gov. 1 November 2020. NCT04608305.
  149. ^ "Phase 2b Dose-confirmatory Trial to Evaluate the Safety, Immunogenicity and Potential Efficacy of an VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE001)". ClinicalTrials.gov. 29 July 2021. NCT04990466. Retrieved 4 August 2021.
  150. ^ "As Israel goes vaccine-wild, will the homegrown version lose its shot?". The Times of Israel. 29 December 2020. Retrieved 1 January 2021.
  151. ^ "Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine (COVID-19)". ClinicalTrials.gov. 15 July 2021. NCT04962893. Retrieved 15 July 2021.
  152. ^ "Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults (COVID-19)". ClinicalTrials.gov. 26 March 2021. NCT04818281. Retrieved 3 April 2021.
  153. ^ "A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19". ClinicalTrials.gov. 26 July 2021. NCT04977024. Retrieved 26 July 2021.
  154. ^ "A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19". ClinicalTrials.gov. 20 November 2020. NCT04639466. Retrieved 21 March 2021.
  155. ^ "Another Chinese adenovirus vector COVID-19 vaccine ready for human trials". Xinhua. 28 December 2020. Retrieved 27 July 2021.
  156. ^ "A Phase II Clinical Trial of the Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector)". chictr.org.cn. 2 August 2021. ChiCTR2100049530. Retrieved 2 August 2021.
  157. ^ "Phase I Clinical Trial of the Candidate Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector)". chictr.org.cn. 23 May 2021. ChiCTR2100046612. Retrieved 23 May 2021.
  158. ^ "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 8 March 2021. Retrieved 13 April 2021.
  159. ^ "Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 23 August 2021. Retrieved 24 August 2021.
  160. ^ "Safety and Tolerability of ABNCoV2 (COUGH-1)". ClinicalTrials.gov. 9 April 2021. NCT04839146. Retrieved 13 April 2021.
  161. ^ "Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19". Business Wire. 2 August 2021.
  162. ^ "Arcturus Allows Vietnam's Vingroup to Make Covid Vaccines". Bloomberg. 2 August 2021.
  163. ^ "Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus' mRNA Covid-19 vaccine". Yahoo! Finance. 2 August 2021.
  164. ^ "Arcturus to start clinical trial of COVID-19 vaccine in Vietnam". Reuters. 2 August 2021.
  165. ^ "Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine". Biopharma Reporter. 2 August 2021.
  166. ^ "The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (ARCT-154-01)". United States National Library of Medicine. 19 August 2021. NCT05012943. Retrieved 19 August 2021.
  167. ^ "Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern". Clover Biopharmaceutical. 18 May 2021. Retrieved 9 July 2021.
  168. ^ "Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults". United States National Library of Medicine. 6 July 2021. NCT04950751. Retrieved 6 July 2021.
  169. ^ "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC". ClinicalTrials.gov. 5 April 2021. NCT04830800. Retrieved 13 April 2021.
  170. ^ "Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand". ClinicalTrials.gov. 21 February 2021. NCT04764422. Retrieved 7 April 2021.
  171. ^ "Vaccine COVID-19 "made in Vietnam" COVIVAC thử nghiệm giai đoạn 2". VTV. 10 August 2021. Retrieved 12 August 2021.
  172. ^ Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. Retrieved 7 April 2021.
  173. ^ "CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". UK BioIndustry Association. 13 August 2020. Archived from the original on 11 October 2020. Retrieved 23 August 2020.
  174. ^ "Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". Archived from the original on 11 October 2020. Retrieved 23 August 2020.
  175. ^ "A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults". ClinicalTrials.gov. 16 December 2020. NCT04668339. Retrieved 10 March 2021.
  176. ^ "Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021". ClinicalTrials.gov. 28 January 2021. NCT04728347. Retrieved 13 March 2021.
  177. ^ "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines (Press release). 9 March 2021. Retrieved 22 March 2021.
  178. ^ "Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)". ClinicalTrials.gov. 26 February 2021. NCT04773665. Retrieved 15 March 2021.
  179. ^ "Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate". Novavax. 10 May 2021.
  180. ^ "Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine". ClinicalTrials.gov. 14 July 2021. NCT04961541. Retrieved 26 July 2021.
  181. ^ "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate" (Press release). Sanofi. 12 March 2021. Retrieved 20 March 2021.
  182. ^ "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". ClinicalTrials.gov. 15 March 2021. NCT04798027. Retrieved 20 March 2021.
  183. ^ "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 5 March 2021. NCT04783311. Retrieved 20 March 2021.
  184. ^ "Trial registered on ANZCTR". anzctr.org.au. Australian New Zealand Clinical Trials Registry. Retrieved 24 March 2021.
  185. ^ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  186. ^ "Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 20 January 2021. NCT04715997. Retrieved 16 March 2021.
  187. ^ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  188. ^ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
  189. ^ "Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals". ClinicalTrials.gov. 7 June 2021. NCT04915989. Retrieved 8 June 2021.
  190. ^ "Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults". ClinicalTrials.gov. 13 May 2020. NCT04386252. Retrieved 23 March 2021.
  191. ^ "Dendritic Cell Vaccine to Prevent COVID-19". ClinicalTrials.gov. 28 December 2020. NCT04685603. Retrieved 23 March 2021.
  192. ^ "Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers". ClinicalTrials.gov. 9 March 2021. NCT04788459. Retrieved 21 March 2021.
  193. ^ a b "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19". ClinicalTrials.gov. 12 February 2021. NCT04751682. Archived from the original on 24 February 2021.
  194. ^ "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
  195. ^ Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.
  196. ^ "Intranasal COVID-19 vaccine Phase 2 study in Healthy volunteers". ctri.nic.in. Clinical Trials Registry India. Retrieved 3 September 2021.
  197. ^ "ChulaCov19 mRNA Vaccine in Healthy Adults". ClinicalTrials.gov. 28 September 2020. NCT04566276. Retrieved 21 March 2021.
  198. ^ a b "Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov. 9 March 2020. NCT04299724. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  199. ^ a b "About Us". Shenzhen Genoimmune Medical Institute. Archived from the original on 11 October 2020. Retrieved 1 August 2020.
  200. ^ a b "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov. 19 February 2020. NCT04276896. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  201. ^ "COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults". ClinicalTrials.gov. 14 January 2021. NCT04710303. Retrieved 23 March 2021.
  202. ^ "COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA". ClinicalTrials.gov. 1 February 2021. NCT04732468. Retrieved 23 March 2021.
  203. ^ "COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers". ClinicalTrials.gov. 19 October 2020. NCT04591717. Retrieved 23 March 2021.
  204. ^ "COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines". ClinicalTrials.gov. 14 April 2021. NCT04845191. Retrieved 22 April 2021.
  205. ^ "COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines". ClinicalTrials.gov. 13 April 2021. NCT04843722. Retrieved 22 April 2021.
  206. ^ a b "Made-in-Canada coronavirus vaccine starts human clinical trials". Canadian Broadcasting Corporation. 26 January 2021.
  207. ^ "PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64". ClinicalTrials.gov. 21 February 2021. NCT04765436. Retrieved 22 April 2021.
  208. ^ a b "VIDO COVID-19 vaccine moves to Phase 1 clinical testing". globalnews.ca. 10 February 2021.
  209. ^ "A Clinical Trial of COVAC-2 in Healthy Adults". ClinicalTrials.gov. 8 January 2021. NCT04702178. Retrieved 20 April 2021.
  210. ^ "Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine". mint. 22 September 2020.
  211. ^ "Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19". ClinicalTrials.gov. 6 November 2020. NCT04619628.
  212. ^ "A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults". ClinicalTrials.gov. 17 February 2021. NCT04758962.
  213. ^ "COVALIA study update: first healthy volunteers dosed in needle-free SARS-CoV2 DNA vaccine phase 1 trial". Bionet Asia. 30 June 2021. Retrieved 19 July 2021.
  214. ^ "The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)". ClinicalTrials.gov. 8 February 2021. NCT04742842.
  215. ^ "Meissa Announces IND Clearance for Phase 1 Study of Intranasal Live Attenuated Vaccine Candidate for COVID-19". Business Wire. 16 March 2021. Retrieved 20 March 2021.
  216. ^ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". ClinicalTrials.gov. 15 March 2021. NCT04798001. Retrieved 20 March 2021.
  217. ^ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 21 March 2021.
  218. ^ "KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers". ClinicalTrials.gov. 16 July 2020. NCT04473690. Retrieved 21 March 2021.
  219. ^ "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". ClinicalTrials.gov. 14 December 2020. NCT04666012. Retrieved 23 March 2021.
  220. ^ "A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine". ClinicalTrials.gov. 21 August 2020. NCT04522089. Retrieved 21 March 2021.
  221. ^ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
  222. ^ "GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)". ClinicalTrials.gov. 17 December 2020. NCT04673149. Retrieved 21 March 2021.
  223. ^ "A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults". ClinicalTrials.gov. 19 October 2020. NCT04591184. Retrieved 21 March 2021.
  224. ^ "Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)". ClinicalTrials.gov. 18 February 2021. NCT04760743. Retrieved 21 March 2021.
  225. ^ "Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)". ClinicalTrials.gov. 14 September 2020. NCT04546841. Retrieved 21 March 2021.
  226. ^ "B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency (B-pVAC)". ClinicalTrials.gov. 8 July 2020. NCT04954469. Retrieved 8 July 2021.
  227. ^ "Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19". ClinicalTrials.gov. 6 April 2020. NCT04334980. Retrieved 21 March 2021.
  228. ^ "CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12)". ClinicalTrials.gov. 13 November 2020. NCT04627675. Retrieved 21 March 2021.
  229. ^ "Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults". ClinicalTrials.gov. 1 March 2021. NCT04776317. Retrieved 22 March 2021.
  230. ^ "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 24 September 2020. NCT04563702. Retrieved 22 March 2021.
  231. ^ "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)". ClinicalTrials.gov. 22 April 2021. NCT04854746. Retrieved 25 May 2021.
  232. ^ "SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 5 March 2021. NCT04784767. Retrieved 24 March 2021.
  233. ^ "Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19". ClinicalTrials.gov. 29 September 2020. NCT04569383. Retrieved 24 March 2021.
  234. ^ "Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (MVA-SARS-2-ST)". ClinicalTrials.gov. 20 May 2021. NCT04895449. Retrieved 21 May 2021.
  235. ^ "Safety, Reactogenicity and Immunogenicity Study of ReCOV". ClinicalTrials.gov. 26 March 2021. NCT04818801. Retrieved 2 April 2021.
  236. ^ "Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo". ClinicalTrials.gov. 8 April 2021. NCT04838080. Retrieved 3 April 2021.
  237. ^ "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 24 March 2021. NCT04813796. Retrieved 17 August 2021.
  238. ^ "Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan" (PDF) (Press release). Daiichi Sankyo. Retrieved 17 April 2021.
  239. ^ "Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up". Fierce Biotech. 22 March 2021. Retrieved 12 April 2021.
  240. ^ "Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects". ClinicalTrials.gov. 29 March 2021. NCT04821674. Retrieved 12 April 2021.
  241. ^ "First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects". ClinicalTrials.gov. 19 May 2021. NCT04893512. Retrieved 26 May 2021.
  242. ^ "Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 22 March 2021.
  243. ^ "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン（KD-414）の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 7 May 2021.
  244. ^ "OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine". BioSpace. 1 April 2021. Retrieved 13 April 2021.
  245. ^ "To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT 3)". ClinicalTrials.gov. 13 May 2021. NCT04885361. Retrieved 13 May 2021.
  246. ^ "Phase 1 Study to Assess Safety, Reactogenicity and Immunogenicity of the HDT-301 Vaccine Against COVID-19". ClinicalTrials.gov. 14 April 2021. NCT04844268. Retrieved 4 August 2021.
  247. ^ "A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers". ClinicalTrials.gov. 9 April 2021. NCT04839042. Retrieved 17 April 2021.
  248. ^ "Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (COVID-19)". ClinicalTrials.gov. 29 April 2021. NCT04866069. Retrieved 30 April 2021.
  249. ^ "Safety and Immunogenicity of EXG-5003". ClinicalTrials.gov. 28 April 2021. NCT04863131. Retrieved 2 May 2021.
  250. ^ "Randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of mRNACOVID-19 vaccine in healthy susceptible populations aged 18 years and older people". Chinese Clinical Trial Registry (ChiCTR). Retrieved 15 May 2021.
  251. ^ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate". Icosavax. 8 June 2021.
  252. ^ "A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine (IVX-411) in Healthy Adults". Australian New Zealand Clinical Trials Registry. Retrieved 14 June 2021.
  253. ^ "НАЧАТЫ КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ СУБЪЕДИНИЧНОЙ ВАКЦИНЫ ПРОТИВ COVID-19, РАЗРАБОТАННОЙ УЧЁНЫМИ НИИПББ". Biosafty and Biotechnology Journal. 15 June 2021.
  254. ^ "Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine". ClinicalTrials.gov. 18 June 2021. NCT04930003. Retrieved 22 June 2021.
  255. ^ "Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 (COVAC-Uganda)". ClinicalTrials.gov. 22 June 2021. NCT04934111. Retrieved 22 June 2021.
  256. ^ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
  257. ^ "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
  258. ^ Rujivanarom, Pratch (6 June 2021). "Local jabs yet to join Covid fight". Bangkok Post. Retrieved 8 July 2021.
  259. ^ "A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19". ClinicalTrials.gov. 7 July 2021. NCT04953078. Retrieved 7 July 2021.
  260. ^ "Phase 1 Intranasal Parainfluenza Virus Type 5-SARS CoV-2 S Vaccine in Healthy Adults (CVXGA1-001)". ClinicalTrials.gov. 8 July 2021. NCT04954287. Retrieved 8 July 2021.
  261. ^ "FMBA begins clinical trials of its coronavirus vaccine, press service says". Russian News Agency. 19 July 2021. Retrieved 20 July 2021.
  262. ^ "Phase I clinical trial to evaluate the safety, tolerability and preliminary immunogenicity of the new coronavirus mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over". chictr.org.cn. 31 July 2021. ChiCTR2100049349. Retrieved 31 July 2021.
  263. ^ Limon, Raul (12 August 2021). "First Spanish Covid-19 vaccine approved for human clinical trial". El Pais. Retrieved 15 August 2021.
  264. ^ "Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)". clinicaltrials.gov. 16 August 2021. NCT05007509. Retrieved 16 August 2021.
  265. ^ "Randomized Controlled-trial to Evaluate Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized". clinicaltrials.gov. 23 August 2021. NCT05016934. Retrieved 23 August 2021.
  266. ^ "A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults". clinicaltrials.gov. 8 September 2021. NCT05037097. Retrieved 8 September 2021.
  267. ^ "Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) (COVER)". clinicaltrials.gov. 8 September 2021. NCT05037188. Retrieved 8 September 2021.
  268. ^ "신형코로나비루스후보왁찐을 새로 개발". North's State Commission of Science and Technology. Archived from the original on 4 May 2021.
  269. ^ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
  270. ^ "Dự kiến cuối quý 3-2021, Việt Nam sẽ có vaccine phòng Covid-19 đầu tiên". Nhân Dân. 22 March 2021. Retrieved 25 March 2021.
  271. ^ "INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies". Inovio Pharmaceutical. 12 May 2021. Retrieved 10 June 2021.
  272. ^ "Bangavax Vaccine: Permission sought for clinical trial". The Daily Star. 18 January 2021.
  273. ^ "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. 8 January 2021.
  274. ^ "Bangavax first buzzed with hope, then fizzled". bdnews24. 6 May 2021. Retrieved 9 May 2021.
  275. ^ "The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunization" (PDF). Indian Immunologicals. 8 April 2020. Retrieved 24 July 2021.
  276. ^ Medeiros, Danielle (31 December 2020). "EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19". EpiVax.
  277. ^ "Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine". Intravacc. 7 April 2021. Retrieved 5 September 2021.
  278. ^ "Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study". CureVac. 13 May 2021.
  279. ^ "Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate "DYAI-100" and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics". Sorrento Therapeutics. 11 August 2021. Retrieved 20 August 2021.
  280. ^ "Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern". Sorrento Therapeutics. 19 August 2021. Retrieved 20 August 2021.
  281. ^ "Malaysian mRNA vaccine against Covid-19 under development, says Adham". The Edge. 21 June 2021. Retrieved 22 June 2021.
  282. ^ "Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)". ClinicalTrials.gov. 22 December 2020. NCT04679909. Retrieved 22 March 2021.
  283. ^ "Altimmune Announces Update On AdCOVID Phase 1 Clinical Trial". Altimmune. 29 June 2021. Retrieved 1 July 2021.
  284. ^ Ward D, McCormack S (22 May 2020). "Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women". ISRCTN. doi:10.1186/ISRCTN17072692. ISRCTN17072692.
  285. ^ "Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)". ClinicalTrials.gov. 4 August 2020. NCT04497298. Retrieved 23 March 2021.
  286. ^ "A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov. 3 August 2020. NCT04495933. Archived from the original on 11 October 2020. Retrieved 4 August 2020.
  287. ^ "UQ-CSL V451 Vaccine". precisionvaccinations.com. Retrieved 11 December 2020.
  288. ^ "Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)". 30 September 2020. Retrieved 26 January 2021.
  289. ^ "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)". 4 August 2020. Retrieved 26 January 2021.
  290. ^ "Participant Enrollment Begins for Phase I Trial of IAVI-Merck COVID-19 Vaccine Candidate". IAVI. Retrieved 14 March 2021.
  291. ^ "V591 SARS-CoV-2 Vaccine". www.precisionvaccinations.com. Retrieved 14 March 2021.
  292. ^ "Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates". Merck (Press release). 25 January 2021. Retrieved 25 January 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Template:COVID-19_vaccine_candidates&oldid=1044393747"